Publications

Shah, NP. The promise of allosteric kinase inhibition. Blood 2024 Nov 7; 144(19)1975-1976. View

Leyte-Vidal A, R DeFilippis, IR Outhwaite, I Kwan, JY Lee, C Leavitt, KB Miller, D Rea, AM Rangwala, K Lou, S Patel, A Alvarez, KM Shokat, I Bahar, MA Seeliger and NP Shah. Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib. Leukemia 2024 Sep; 38(9):2046-2050. View

Leyte-Vidal, A, D Garrido Ruiz, R DeFilippis, IB Leske, D Rea, S Phan, KB Miller, F Hu, A Mase, Y Shan, O Hantschel, MP Jacobson, and NP Shah. BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib. Blood 2024 Aug 8; 144(6):639-645. View

Wang, X, RA DeFilippis, W Yan, NP Shah and HY Li. Overcoming secondary mutations of type II kinase inhibitors. J Med Chem 2024 Jun 27;67(12):9776-9788. View

Berman, E, NP Shah, M Deininger, JK Altman, M Amaya, K Begna, R Bhatia, O Chan, R Collins, P Curtin, DJ DeAngelo, M Drazer, L Maness, L Metheny, S Mohan, J Moore, V Oehler, K Pratz, I Pusic, M Rose, W Shomali, BD Smith, M Styler, K Sweet, M Talpaz, T Tanaka, S Tantravahi, S Tsai, J Vaughn, J Welborn, D Yang, M Mauro, J Cortes, J Radich and B Druker. CML and the WHO: Why? J Clin Oncol 2024 Mar 20;42(9):984-986. View

Jabbour, E, J Apperley, J Cortes, D Rea, M Deininger, E Abruzzese, C Chuah, DJ DeAngelo, A Hochhaus, JH Lipton, M Mauro, F Nicolini, J Pinilla-Ibarz, G Rosti, P Rousselot, NP Shah, M Talpaz, A Vorog, X Ren and H Kantarjian. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 2024 Mar;38(3):475-481. View

Shah, NP, R Bhatia, JK Altman, M Amaya, KH Begna, E Berman, O Chan, J Clements, RH Collins, PT Curtin, DJ DeAngelo, M Drazer, L Maness, L Metheny, S Mohan, JO Moore, V Oehler, K Pratz, I Pusic, MG Rose, W Shomali, BD Smith, M Styler, M Talpaz, TN Tanaka, S Tantravahi, J Thompson, S Tsai, J Vaughn, J Welborn, DT Yang, H Sundar and K Gregory. Chronic myeloid leukemia, version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2024 Feb;22(1):43-69. View

Wang X,DeFilippis RA, Leung YK, NP Shah and Li HY. N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD/D835Y and FLT3-ITD/F691L secondary mutants. Bioorg Chem. 2024 Feb; 143:106966, 2024. View

Wang, X, RA DeFilippis, T Weldemichael, N Gunaganti, P Tran, YK Leung, NP Shah, and HY Li. An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L. Eur J Med Chem. 2024 Jan 15; 264: 115977. View

Winn AN, E Atallah, J Cortes, MWN Deininger, V Kota, RA Larson, JO Moore, MJ Mauro, VG Oehler, J Pinilla-Ibarz, NP Shah, JE Thompson and KE Flynn. Estimated savings after stopping tyrosine kinase inhibitor treatment among patients with chronic myeloid leukemia. JAMA Netw Open 2023 Dec 1; 6(12):e2347950. View

NP Shah, V Garcia-Gutierrez, A Jiminez-Velasco, SM Larson, S Saussele, D Rea, FX Mahon, MY Levy, MT Gomez-Casares, MJ Mauro, O Sy, P Martin-Regueira and JH Lipton. Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE. Br J Haematol 2023 Sep; 202(5):942-952. View

Szeto MY, Mase A, Kayla Kulhanek, Saikat Banerjee, Ignacio Rubio, Jeroen Roose, NP Shah. A critical role for PLCG1 in RAS activation by BCR-ABL1 and FLT3-ITD. bioRxiv [Preprint]. 2023 April; doi.org/10.1101/2023.04.07.536070. View

Kantarjian, HM, E Jabbour, M Deininger, E Abruzzese, J Apperley, J Cortes, C Chuah, DJ DeAngelo, J DiPersio, A Hochhaus, J Lipton, FE Nicolini, J Pinilla-Ibarz, D Rea, G Rosti, P Rousselot, NP Shah, M Talpaz, S Srivastava, X Ren and M Mauro. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia. Am J Hematol 2022 Nov; 97(11):1419-1426. View

Flynn, KE, E Atallah, L Li, NP Shah, RT Silver, RA Larson, J Pinilla-Ibarz, JE Thompson, VG Oehler, RP Radich, V Kota, MJ Mauro, CA Schiffer, J Cortes and KP Weinfrut. Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia. Haematologica 2022 Nov 1; 107(11):2641-2649. View

Schoenbeck, KL, E Atallah, L Lin, KP Weinfurt, J Cortes, MWN Deininger, V Kota, RA Larson, MJ Mauro, VG Oehler, J Pinilla-Ibarz, JP Radich, CA Schiffer, NP Shah, RT Silver, JE Thompson and KE Flynn. Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors.  J Natl Cancer Inst 2022 Jan; 114: 160-164. View

Zhang, L, NR Lakkaniga, JB Bharate, N McConnell, X Wang, A Kharbanda, YK Leung, B Frett, NP Shah and HY Li. Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor. Eur J Med Chem 2021 Dec 5; 225:113776. View

Tran, TH, JV Nguyen, A Stecula, J Akutagawa, AV Moorman, BS Braun, A Sali, CG Mullighan, NP Shah, Y Dai, M Devidas, KG Roberts, CC Smith and ML Loh. 2021. The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment. Haematologica 2021 Aug; 106:2242-2245. View

Smith, CC, AD Viny, E Massi, C Kandoth, ND Socci, F Rapaport, M Najm, JS Medina-Martinez, E Papaemmanuil, TC Tarver, HH Hsu, B West, G Bollag, BS Taylor, RL Levine and NP Shah. Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Clin Cancer Res 2021 Jun; 27:4003-4011. View

Mali, RS, Q Zhang, R DeFilippis, R Cavazos, VM Kuruvilla, J Raman, V Mody, EF Choo, M Dail, NP Shah, M Konopleva, D Sampath and EA Lasater. 2021. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models. Haematologica 2021 April; 106:1034-1046. View

Atallah, E, CA Schiffer, JP Radich, KP Weinfurt, MJ Zhang, J Pinilla-Ibarz, V Kota, RA Larson, JO Moore, MJ Mauro, MWN Deininger, JE Thompson, VG Oehler, M Wadleigh, NP Shah, EK Ritchie, RT Silver, J Cortes, L Lin, A Visotcky, A Baim, J Harrell, B Helton, M Horowitz and KE Flynn. 2021. Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial. JAMA Onc 2021 Jan; 7:42-50. View

Shah, NP, V Garcia-Gutierrez, A Jimenez-Velasco, S Larson, S Saussele, D Rea, FX Mahon, MY Levy, MT Gomez-Casares, F Pane, FE Nicolini, MJ Mauro, O Sy, P Martin-Regueira and JH Lipton. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leukemia & Lymphoma 2020 March; 61:650-659. View

Apsel-Winger, B, WA Cortopassi, D Garrido Ruiz, L Ding, K Jang, A Leyte-Vidal, N Zhang, R Esteve-Puig, MP Jacobson and NP Shah. ATP-competitive inhibitors midostaurin and avapritinib have distinct resistance profiles in exon 17-mutant KIT. Cancer Research 2019 Aug; 79:4283-4292. View

McMahon, CM, T Ferng, J Canaani, ES Wang, JJD Morrissette, DJ Eastburn, M Pellegrino, R Durruthy-Durruthy, CD Watt, S Asthana, EA Lasater, R DeFilippis, CAC Peretz, LHF McGary, S Deihimi, AC Logan, SM Luger, NP Shah, M Carroll, CC Smith and AE Perl. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discovery 2019 Aug; 8:1050-1063. View

Hughes, TP, P Laneuville, P Rousselot, DS Snyder, D Rea, NP Shah, D Paar, E Abruzzese, A Hochhaus, JH Lipton and JE Cortes. Incidence, outcomes and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia.  Haematologica 2019 Jan; 104:93-101. View

Cortes J, AE Perl, H Döhner, H Kantarjian, G Martinelli, T Kovacsovics, P Rousselot, B Steffen, H Dombret, E Estey, S Strickland, JK Altman, CD Baldus, A Burnett, A Krämer, N Russell, NP Shah, CC Smith, ES Wang, N Ifrah, G Gammon, D Trone, D Lazzaretto and M Levis. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 2018 July; 19:889-903. View

Cortes JE, DW Kim, J Pinilla-Ibarz, PD le Coutre, R Paquette, C Chuah, FE Nicolini, JF Apperley, HJ Khoury, M Talpaz, DJ DeAngelo, E Abruzzese, D Rea, M Baccarani, MC Müller, C Gambacorti-Passerini, S Lustgarten, VM Rivera, FG Haluska, F Guilhot, MW Deininger, A Hochhaus, TP Hughes, NP Shah and HM Kantarjian. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 2018 July; 132:393-404. View

Atallah E, CA Schiffer, KP Weinfurt, MJ Zhang, JP Radich, VG Oehler, J Pinilla-Ibarz, MWN Deininger, L Lin, RA Larson, MJ Mauro, JO Moore, EK Ritchie, NP Shah, RT Silver, M Wadleigh, J Cortes, J Thompson, J Guhl, MM Horowitz, and KE Flynn. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. BMC Cancer 2018 April; 18:359-366. View

Bharate JB, N McConnell, G Naresh, L Zhang, NR Lakkaniga, L Ding, NP Shah, B Frett B and HY Li. Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT. Sci Rep 2018 Feb; 8:3722-3739. View

Saglio G, P le Coutre, J Cortes, J Mayer, P Rowlings, FX Mahon, G Kroog, K Gooden, M Subar and NP Shah. Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.  Ann Hematol  2017 Aug; 96:1303-1313. View

Smith CC, A Paguirigan, GR Jeschke, KC Lin, E Massi, T Tarver, CS Chin, S Asthana, A Olshen, KJ Travers, S Wang, MJ Levis, AE Perl and NP Shah. Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis.  Blood 2017 July; 130:48-58. View

Metts J, HL Bradley, Z Wang, NP Shah, R Kapur, JL Arbiser and KD Bunting. Imipramine blue sensitivity and selectivity targets FLT3-ITD positive acute myeloid leukemia cells. Sci Rep 2017 June; 7:4447-4456. View

Lee BJ and NP Shah. Identification and characterization of activating ABL1 1b kinase mutations: impact on sensitivity to ATP-competitive and allosteric ABL1 inhibitors. Leukemia 2017; 31:1096-1107. View

Shah NP, P Rousselot, C Schiffer, D Rea, JE Cortes, J Milone, H Mohamed, D Healey, H Kantarjian, A Hochhaus and G Saglio. Dasatinib in imatinib-resistant or –intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol 2016 Sept; 91:869-874. View

Le Coutre PD, TP Hughes, FX Mahon, DW Kim, JL Steegman, NP Shah, K Gooden, N Wallis and JE Cortes. Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials. Leukemia 2016 July; 7:1593-1596 View

Cortes JE, G Saglio, HM Kantarjian, M Baccarani J Mayer, C Boque, NP Shah, C Chuah, L Casanova, B Bradley-Garelik, G Manos and A Hochhaus. Final 5-year study results of DASISION: the dasatinib vs imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Onc 2016 July; 34:2333-2340. View

Lasater EA, ES Massi, A Stecula, J Politi, SK Tan, CC Smith, M Gunthorpe, F Chehab, A Sali and NP Shah. Novel TKI-resistant BCR-ABL1 gatekeeper residue mutations retain in vitro sensitivity to axitinib. Leukemia 2016 June; 6:1405-1409. View

Lipton CH, C Chuah, A Guerci-Bresler, G Rosti, D Simpson, S Assouline, G Etienne, FE Nicolini, P le Coutre, RE Clark, L Stenke, D Andorsky, V Oehler, S Lustgarten, VM Rivera, T Clackson, FG Haluska, M Baccarani, JE Cortes, F Guilhot, A Hochhaus, T Hughes, HM Kantarjian, NP Shah, M Talpaz and MW Deininger. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukemia leukaemia: an international, randomized, open-label, phase 3 trial. Lancet Oncol 2016 May; 17:612-621. View

Schiffer CA, JE Cortes, A Hochhaus, G Saglio, P leCoutre, K Porkka, S Mustjoki, H Mohamed and NP Shah. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. Cancer 2016 Mar; 122:1398-1407. View

Minson, KA, CC Smith, D DeRyckere, C Libbrecht, AB Lee-Sherick, MG Huey, EA Lasater, GD Kirkpatrick, MA Stashko, W Zhang, CT Jordan, D Kireev, X Wang, SV Frye, HS Earp, NP Shah and DK Graham. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight 2016 Mar; 1:e85630. View

Deininger MW, JG Hodgson, NP Shah, JE Cortes, DW Kim, FE Nicolini, M Talpaz, M Baccharani, MC Muller, J Li, WT Parker, S Lustgarten, T Clackson, FG Haluska, F Guilhot, HM Kantarjian, S Soverini, A Hochhaus, TP Hughes, VM Rivera and S Branford. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood 2016 Feb; 127:703-712. View

Nybakken GE, J Canaani, D Roy, JD Morrissette, CD Watt, NP Shah, CC Smith, A Bagg, M Carroll, AE Perl.  Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone.  Leukemia 2015 Nov; 6:1422-1425. View

Apsel Winger B and NP Shah. PPARg: Welcoming the new kid on the CML stem cell block. Cancer Cell 2015 Oct; 28:409-411. View

Kesarwani M, E Huber, Z Kincaid, CR Evelyn, J Biesiada, M Rance, MB Thapa, NP Shah, J Meller, Y Zheng and M Azam. Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance. Sci Rep 2015 Sept; 5:14538. View

Smith CC, K Lin, A Stecula, A Sali and NP Shah. FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors.  Leukemia 2015 Jun; 29: 2390-2392. View

Smith CC, C Zhang, K Lin, EA Lasater, Y Zhang, E Massi, LE Damon, M Pendleton, A Bashir, RP Sebra, AE Perl, A Kasarskis, R Shellooe, G Tsang, H Carias, B Powell, EA Burton, B Matusow, J Zhang, W Spevak, PN Ibrahim, MH Le, H Hsu, GG Habets, BL West, G Bollag and NP Shah. Characterizing and overriding the structural mechanism of the quizartinib-resistant FLT3 “gatekeeper” F691L mutation with PLX3397. Cancer Discovery 2015 Jun; 6:668-679. View

Frett, B, N McConnell, C Smith, Y Wang, NP Shah, and H Li. Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors. Eur J Med Chem 2015 April; 94:123-131. View

Warkentin, AA, MS Lopez, EA Lasater, K Lin, B He, AY Leung, CC Smith*, NP Shah* and KM Shokat*. Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy. Elife 2014 Dec 22 *contributed equally. View

Chatterjee, A, J Ghosh, B Ramdas, RS Mali, H Martin, M Kobayashi, S Vemula, VH Canela, ER Waskow, V Visconte, RV Tiu, CC Smith, NP Shah, KD Bunting, HS Boswell, Y Liu, RJ Chan and R Kapur. Regulation of Stat 5 by FAK and PAK1 by oncogenic FLT3- and KIT-driven leukemogenesis. Cell Rep 2014 Nov; 9:1333-1348. View

Tajon, CA, D Seo, J Asmussen, NP Shah, YW Jun and C Craik. Sensitive and selective plasmon ruler nanosensors for monitoring the apoptotic drug response in leukemia. ACS Nano 2014 Sept; 8:9199-9208. View

Smith CC, EA Lasater, KC Lin, Q Wang, MQ McCreery, WK Stewart, LE Damon, AE Perl, GR Jeschke, M Sugita, M Carroll, SC Kogan, J Kuriyan and NP Shah. Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci 2014 April; 111(14):5319-24. View

Ciceri, P, S Muller, A Mahony, O Fedorov, P Filippakopoulos, JP Hunt, EA Lasater, G Pallares, S Picaud, C Wells, S Martin, LM Wodicka, NP Shah, DK Treiber and S Knapp. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat Chem Biol 2014 April; 10:305-312. View

Shah NP, G Guilhot, JE Cortes, CA Schiffer, P le Coutre, TH Brummendorf, HM Kantarjian, A Hochhaus, P Rousselot, H Mohamed, D Healey, M Cunningham and G Saglio. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of phase 3 study. Blood 2014 April; 123:2317-2324. View

Verstovsek, S, CS Tam, M Wadleigh, L Sokol, CC Smith, LA Bui, C Song, DO Clary, P Olszynski, J Cortes, H Kantarjian and NP Shah. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leuk Res 2014 March; 38: 316-322. View

Asmussen J, EA Lasater, C Tajon, J Oses-Prieto, YW Jun, BS Taylor, A Burlingame, CS Craik and NP Shah. MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction. Cancer Discovery 2014 Feb; 4:200-215. View

Jabbour, E, HM Kantarjian, G Saglio, JL Steegmann, NP Shah, C Boque, C Chuah, C Pavlovsky, J Mayer, J Cortes, M Baccarani, DW Kim, MB Bradley-Garelik, H Mohamed, M Wildgust and A Hochhaus. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 study (DASISION). Blood 123:494-500. View

Politi, J and NP Shah. What does a deep molecular response signify? J Clin Onc 2014 Feb; 32: 471-474. View

Soverini, S, S Branford, FE Nicolini, M Talpaz, MW Deininger, G Martinelli, MC Muller, JP Radich and NP Shah. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res 2014 Jan; 38:10-20. View

Cortes, JE, DW Kim, J Pinilla-Ibarz, P le Coutre, R Paquette, C Chuah, FE Nicolini, JF Apperley, HJ Khoury, M Talpaz, J DiPersio, DJ DeAngelo, E Abruzzese, D Rea, M Baccarani, MC Muller, C Gambacorti-Passerini, S Wong, S Lustgarten, VM Rivera, T Clackson, CD Turner, FG Haluska, F Guilhot, MW Deininger, A Hochhaus, T Hughes, JM Goldman, NP Shah, H Kantarjian; PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.  NEJM 2013 Nov; 369:1783-1796. View

O’Brien, S, JP Radich, CN Abboud, M Akhtari, JK Altman, E Berman, DJ DeAngelo, M Deininger, S Devine, AT Fathi, J Gotlib, M Jagasia, P Kropf, JO Moore, A Pallera, J Pinilla-Ibarz, VV Reddy, NP Shah, BD Smith, DS Snyder, M Wetzler, K Gregory and H Sundar. Chronic myelogenous leukemia, version 1.2014.  J Natl Compr Canc Netw 2013 Nov; 11:1327-1340. View

Shah NP, M Talpaz, MW Deininger, MJ Mauro, IW Flinn, D Bixby, S Lustgarten, JM Gozgit, T Clackson, CD Turner, FG Haluska, H Kantarjian and JE Cortes. Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study.  Br J Haematol 2013 Aug; 162:548-552. View

Trieber, DK and NP Shah. The ins and outs of kinase DFG motifs. Chem Biol 2013 Jun; 20:745-746. View

Wang X, A Roy, A Hochhaus, HM Kantarjian, TT Chen and NP Shah. Differential effects of dosing regimen on the safety and efficacy of dasatinib: exposure-response analysis of a phase III study. Clin Pharmacol 2013 Jun; 5:85-97. View

Shah, NP. Getting personal with cancer.  Nat Med 2013 Jun; 19:665. View

Smith, CC and NP Shah. The role of kinase inhibitors for the treatment of patients with acute myeloid leukemia. ASCO Educ Book; 2013:313-318. View

Sonnichsen, D, DJ Dorer, J Cortes, M Talpaz, MW Deininger, NP Shah, HM Kantarjian, D Bixby, MJ Mauro, IW Flinn, J Litwin, CD Turner and FG Haluska. Analysis of the potential effect of ponatinib on QTc interval in patients with refractory hematological malignancies. Cancer Chemother Parmacol 2013 Apr; 71:1599-1607. View

Smith, CC, EA Lasater, X Zhu, KC Lin, WK Stewart, LE Damon, S Salerno and NP Shah. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants. Blood 2013 Feb; 121:3165-3171. View

Cortes, JE, H Kantarjian, NP Shah, D Bixby, MJ Mauro, I Flinn, T O’Hare, S Hu, NI Narasimhan, VM Rivera, T Clackson, CD Turner, FG Haluska, BJ Druker, MWN Deininger and M Talpaz. Ponatinib in refractory Philadelphia chromosome-positive leukemias. NEJM 2012 Nov; 367:2075-2088. View

Roberts, KG, RD Morin, J Zhang, M Hirst, Y Zhao, X Su, SC Chen, D Payne-Turner, ML Churchman, RC Harvey, X Chen, C Kasap, C Yan, J Becksfort, RP Finney, DT Teachey, SL Maude, K Tse, R Moore, S Jones, K Mungall, I Birol, MN Edmonson, Y Hu, KE Buetow, IM Chen, WL Carroll, L Wei, J Ma, M Klepp, RL Levine, G Garcia-Manero, E Larsen, NP Shah, M Devidas, G Reaman, M Smith, SW Paugh, WE Evans, SA Grupp, S Jeha, CH Pui, DS Gerhard, JR Downing, CL Willman, M Loh, SP Hunger, MA Marra, and CG Mullighan. Genetic alterations in activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012 Aug; 22:153-166. View

Smith, CC, Q Wang, C-S Chin, S Salerno, LE Damon, MJ Levis, AE Perl, KJ Travers, S Wang, JP Hunt, PP Zarrinkar, EE Schadt, A Kasarskis, J Kuriyan, J. and NP Shah. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature (London) 2012 Apr; 485:260-263. View

Shah NP and K Shannon. Advancing the STATus of MPN pathogenesis.  Blood 2012 Apr; 119:3374-3376. View

O’Brien, S, CN Abboud, M Akhtari, JK Altman, E Berman, DJ DeAngelo, S Devine, AT Fathi, J Gotlib, M Jagasia, JO Moore, J Pinilla-Ibarz, JP Radich, VV Reddy, NP Shah, PJ Shami, BD Smith, DS Snyder, M Wetzler, F Yunus; National Comprehensive Cancer Network. Chronic myelogenous leukemia. J Natl Compr Canc Netw 2012; 10:64-110.

Kantarjian, HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, Wang J, Kassack Ipiña JJ, Kim DW, Ogura M, Pavlovsky C, Junghanss C, Milone JH, Nicolini FE, Robak T, Van Droogenbroeck J, Vellenga E, Bradley-Garelik MB, Zhu C, Hochhaus A. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012 Feb; 119:1123-1129. View

Smith, CC and NP Shah. Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naïve or refractory chronic phase disease. Hematology (Am Soc Hematol Educ Program) 2011:371-375. View

Smith, CC and NP Shah. Is it Downhill from here?  Eliminating Leukemic Stem Cells and Curing CML. Clin Cancer Res 2011 Nov; 17:6605-6607. View

Hurtz, C, K Hatzi, L Cerchietti, M Braig, E Park, YM Kim, S Herzog, P Ramezani-Rad, H Jumaa, MC Muller, WK Hofmann, A Hochhaus, BH Ye, A Agarwal, NP Shah, AM Melnick and M Muschen. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med 2011 Oct; 208:2163-2174. View

Paquette, RL, J Nicoll, M Chalukya, D Elashoff, NP Shah, C Sawyers, E Spiteri, G Nanjangud and PN Rao. Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors. Cancer Genet 2011 July; 204:392-297. View

Kantarjian*, H, NP Shah*, A Hochhaus, J Cortes, S Shah, M Ayala, B Moiraghi, Z Shen, J Mayer, R Pasquini, H Nakamae, F Huguet, C Boque, C Chuah, E Bleickardt, MB Bradley-Garelik, C Zhu, T Szatrowski, D Shapiro and M Baccarani. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. *contributed equally; NEJM 2010 Jun; 362:2260-2270.  View

Paquette, RL, J Nicoll, M Chalukya, L Gondek, M Jasek, CL Sawyers, NP Shah and J Maciejewski. Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib. Leuk Res 2010 Jun; 34:708-713. View

Lilly, MJ, OG Ottmann, NP Shah, RA Larson, JJ Reiffers, G Ehninger, MC Muller, A Charbonnier, E Bullorsky, H Dombret, B Bradley-Garelik, C Zhu and G Martinelli. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol 2010 Mar; 85:164-170. View

Shah, NP, DW Kim, H Kantarjian, P Rousselot, PE Llacer, A Enrico, J Vela-Ojeda, RT Silver, HJ Khoury, MC Muller, A Lambert, Y Matloub and H Hochhaus. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010 Feb; 95:232-240. View

Shah, NP. Fine-tuning targeted therapy of CML. Blood 2019 Dec; 114:4914-4915. View

Kantarjian, H, R Pasquini, V Levy, S Jootar, N Hamerschlak, T Hughes, E Bleickardt, D Dejardin, J Cortes and NP Shah. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2019 Sept; 115:4136-4147. View

Mustjoki, S,  M Ekblom, TP Arstila, I Dybedal, PK Epling-Burnette, F Guilhot, H Hjorth-Hansen, M Hoglund,  P Kovanen, T Laurinolli, J Liesveld, R Paquette, J Pinilla-Ibarz, A Rauhala, N Shah, B Simonsson, M Sinisalo, JL Steegmann, L Steinke and K Porkka. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2019 Aug; 23:1398-1405. View

Seeliger, MA, P Ranjitkar, C Kasap, Y Shan, DE Shaw, NP Shah, J Kuriyan and DJ Maly. Equally potent inhibition of c-Src and Abl by compounds that recognized inactive kinase conformations. Cancer Res 2019 Mar; 15:2384-2392. View

Oehler, V, J Qin, R Ramakrishnan, G Facer, S Ananthnarayan, C Cummings, M Deininger, NP Shah, F McCormick, S Willis, A Daridon, M Unger and JP Radich. Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR. Leukemia 2019 Feb; 23:396-399. View

Shah, NP, C Kasap, C Weier, M Balbas, JM Nicoll, E Bleickardt, C Nicaise and CL Sawyers. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 2008 Dec; 14:485-493.  View

Shah, NP, HM Kantarjian, D-W Kim, D Rea, PE Dorlhiac-Llacer, JH Milone, J Vela-Ojeda, RT Silver, HJ Khoury, A Charbonnier, N Khoroshko, RL Paquette, M Deininger, RH Collins, I Otera, T Hughes, E Bleickardt, L Strauss, S Francis and A Hochhaus. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and –intolerant chronic phase chronic myeloid leukemia. J Clin Oncol 2008 July; 26:3204-3212. View

Hochhaus, A, M Baccarani, M Deininger, JF Apperley, JH Lipton, SL Goldberg, S Corm, NP Shah, F Cervantes, RT Silver, D Niederwieser, RM Stone, H Dombret, RA Larson, L Roy, T Hughes, MC Muller, R Ezzedine, AM Countouriotis and HM Kantarjian. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008 Jun; 22:1200-1206. View

Shah, NP. BRCA: From therapeutic target to therapeutic shield. Nature Medicine 2008 May; 14:495-496. View

Shah, NP. Medical Management of CML. Hematology (Am Soc Hematol Educ Program) 2007:371-375. View

Shah, NP. Progressive thoughts about progressive disease. Clin Cancer Res 2007 Sept; 13:5229-5231. View

Shah, NP, BJ Skaggs, S Branford, TP Hughes, JM Nicoll, RL Paquette and CL Sawyers. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007 Sept; 117:2562-2569. View

Kantarjian, H, R Pasquini, N Hamerschlak, P Rousselot, J Holowiecki, S Jootar, T Robak, N Khoroshko, T Masszi, A Skotnicki, A Hellmann, A Zaritsky, A Golenkov, J Radich, T Hughes, A Countouriotis and NP Shah. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase-II trial. Blood 2007 Jun; 109:5143-5150. View

Shankar, DB, J Li, P Tapang, J Owen McCall, LJ Pease, Y Dai, RQ Wei, DH Albert, JJ Bouska, DJ Osterling, J Guo, PA Marcotte, EF Johnson, N Soni, K Hartandi, MR Michaelides, SK Davidsen, SJ Priceman, JC Chang, K Rhodes, NP Shah, TB Moore, KM Sakamoto and KB Glaser. ABT-869, a multi-targeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood 2007 Apr; 109:3400-3408. View

Hochhaus, A, HM Kantarjian, M Baccarini, JH Lipton, JF Apperley, BJ Druker, T Facon, SL Goldberg, F Cervantes, D Niederwieser, RT Silver, RM Stone, TP Hughes, MC Muller, R Ezzeddine, AM Countouriotis and NP Shah. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007 Mar; 109:2303-2309. View

Shah, NP. Dasatinib.  Drugs Today 2007 Jan; 43:5-12. View

Shah, NP.  Improving upon the promise of targeted therapy of human malignancy: chronic myeloid leukemia as a paradigm. Cancer Chemother Pharmacol 58 Suppl 7:49-53.

Shah, NP, FY Lee, R Luo, Y Jiang, M Donker and C Akin. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activation mutation that triggers neoplastic growth in the majority of patients with systemic mastocytosis. Blood 2006 July; 108:286-291. View

Talpaz, M, NP Shah, H Kantarjian, N Donato, J Nicoll, R Paquette, J Cortes, S O’Brien, C Nicaise, E Bleickardt, MA Blackwood-Chirchir, V Iyer, T-T Chen, F Huang, AP Decillis and CL Sawyers. Activity of the ABL kinase inhibitor dasatinib in imatinib-resistant Philadelphia chromosome positive leukemias. NEJM 2006 Jun; 354:2531-2541. View

Radich, JP, H Dai, M Mao, V Oehler, J Schelter, B Druker, C Sawyers, N Shah, W Stock, CL Willman, S Friend and PS Linsley. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006 Feb; 103:2794-2799. View

Young, MA, NP Shah, LH Chao, M Seeliger, ZV Milanov, WH Biggs, DK Treiber, HK Patel, PP Zarrinkar, DJ Lockhart, CL Sawyers and J Kuriyan. Structure of the kinase domain of imatinib-resistant ABL mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 2006 Jan; 66:1007-1014. View

Carter, TA, LM Wodicka, NP Shah, AM Velasco, MA Fabian, DK Treiber, ZV Milanov, CE Atteridge, WH Biggs, PT Edeen, M Floyd, JM Ford, RM Grotzfeld, S Herrgard, DE Insko, SA Mehta, HK Patel, W Pao, CL Sawyers, H Varmus, PP Zarrinkar and DJ Lockhart. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005 Aug; 102:11011-11016. View

Michor, F, TP Hughes, Y Iwasa, S Branford, NP Shah, CL Sawyers and MA Nowak. Dynamics of chronic myeloid leukemia. Nature 2005 Jun; 435:1267-1270. View

Chu, S, H Xu, NP Shah, DS Snyder, SJ Forman, CL Sawyers and R Bhatia. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005 Mar; 105:2093-2098. View

Burgess, MR, BJ Skaggs, NP Shah, FY Lee and CL Sawyers. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA 2005 Mar; 102:3395-3400. View

Shah, NP. Loss of response to imatinib: mechanisms and management.  Hematology (Am Soc Hematol Educ Program) 2005 Jan; 2005:183-187. View

Shah, NP, C Tran, FY Lee, D Norris, P Chen and CL Sawyers. Overriding imatinib resistance with a novel ABL inhibitor. Science 2004 July; 305:399-401. View

Shah, NP, and CL Sawyers. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias.  Oncogene 2003 Oct; 22:7389-7395. View

Shah, NP, JM Nicoll, B Nagar, ME Gorre, RL Paquette, J Kuriyan and CL Sawyers. Multiple BCR-ABLkinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002 Aug; 2:117-125. View

Roumiantsev, S, NP Shah, ME Gorre, JM Nicoll, BB Brasher, CL Sawyers and RA Van Etten. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA 2002 Aug; 16:10700-10705. View

Shah, NP and CL Sawyers. Recent success with the tyrosine kinase inhibitor STI-571 – lessons learned for targeted therapy of cancer.  Curr Opin Invest Drugs 2001 Mar; 2:422-423. View

Withers-Ward, E, JBM Jowett, SA Stewart, Y-M Xie, A Garfinkel, Y Shibagaki, SA Chow, NP Shah, F Hanaoka, DG Sawitz, RW Armstrong, LM Souza and IS-Y Chen. HIV-1 Vpr interacts with HHR23A, a cellular protein implicated in nucleotide excision DNA repair.  J Virology 1997 Dec; 71:9732-9742. View

Jowett, JB, V Planelles, B Poon, NP Shah, M-L Chen and IS-Y Chen. The HIV-1 vpr gene arrests infected T-cells in the G2 + M phase of the cell cycle.  J Virology 1995 Oct; 69:6304-6313. View

Planelles, V, A Haislip, ES Withers-Ward, SA Stewart, Y Xie, NP Shah and IS-Y Chen. A new reporter system for detection of retroviral infection.  Gene Therapy 1995 Aug; 2:369-376. View

Lewis, BC, NP Shah, BS Braun and CT Denny. Creation of a yeast artificial chromosome fragmentation vector based on lysine-2. Genetic Analysis: Techniques and Applications 1992 Jun; 9:86-90. View

Shah, NP, ON Witte and CT Denny. Characterization of the BCR promoter in Philadelphia chromosome-positive and –negative cell lines. Mol Cell Biol 1991 Apr; 11:1854-1860. View

Denny, CT, NP Shah, S Ogden, C Willman, T McConnell, W Crist, A Carroll and ON Witte. Localization of preferential sites of rearrangement within the BCR gene in Philadelphia chromosome-positive acute lymphoblastic leukemia. Proc Natl Acad Sci USA 1989 Jun; 86:4254-4258. View

Rosenblatt JD, AJ Cann, DJ Slamon, IS Smalberg, NP Shah, J Fujii, W Wachsman and IS-Y Chen. HTLV-II trans-activation is regulated by two overlapping nonstructural genes. Science 1988 May; 240:916-919. View

Kitado, H, IS-Y Chen, NP Shah, AJ Cann, K Shimotohno and H Fan. U3 sequences from HTLV-I and –II LTRs confer px protein response to a murine leukemia virus LTR.  Science 1987 Feb; 235:901-904. View

Wachsman, W, AJ Cann, JL Williams, DJ Slamon, L Souza, NP Shah and IS-Y Chen. HTLV x gene mutants exhibit novel transcriptional regulatory phenotypes. Science 1987 Feb; 235:674-677. View

Shah, NP, W Wachsman, L Souza, AJ Cann, DJ Slamon and IS-Y Chen. Comparison of the trans-activation properties of the HTLV-I and HTLV-II x proteins. Mol Cell Biol 1986 Nov; 6:3626-3631. View

Cann, AJ, JD Rosenblatt, W Wachsman, NP Shah and IS-Y Chen. Identification of the gene responsible for human T-cell leukemia virus transcription regulation.  Nature (London) 1985 Dec; 318:571-574. View

Chen, IS-Y, AJ Cann, NP Shah and RB Gaynor. Functional relation between HTLV x and adenovirus EIA proteins in transcriptional activation.  Science 1985 Nov; 230:570-573. View

Chen, IS-Y, DJ Slamon, JD Rosenblatt, NP Shah, SG Quan and W Wachsman. The x gene is essential for HTLV replication.  Science 1985 July; 229:54-58. View